Pharmafile Logo

Insights from the charity sector – from patient engagement to people-driven design

Marianne Guldbrandsen, Strategy Director at Cuttsy+Cuttsy and former Head of Innovation and Strategic Partnerships at Macmillan, discusses how people-driven research leads to truly patient-centred products and services, and what the pharmaceutical industry can learn about this from the charity sector.

- PMLiVE
The charity sector has a reputation for being good at bringing their key stakeholder to the core of everything they do. With the term ‘patient-centric’ being heard more and more in the pharma industry, there are things we can learn from the charity sector about the breadth and depth of how to involve and support patients and their families.

When talking about being patient-centric, the devil is in the detail. We can all agree that engaging patients is important — after all it is their health, care and treatment we are trying to continuously improve. But if engagement is merely a matter of involving them in clinical trials, advisory boards, focus groups or online forums, then we are missing out on great potential for even better insight, innovation and impact.

Being truly patient-centric means being people-driven, a subtle but important difference where we put effort into understanding not just the part of the person that can be described as a patient, but all of them. It is in understanding that people are more than patients that we can really make a difference. They have lives to live, daily activities, work, family, commuting etc. It means that we don’t just bring them into our processes, but we spend time to understand the context in which medicines and treatments are experienced over time. We involve them not just by gaining insights in the early stages, but in letting them participate throughout the development process. Depending on what we are creating it might even be appropriate let them participate in a way that could be described as co-creation. Co-creation means gaining insights and bringing ideas to fruition through prototyping with the end-user involved throughout the process.

- PMLiVE

As an example of how a people-driven approach is being used in the charity sector, Macmillan Cancer Support created a service for younger people affected by cancer using deep customer insights, co-design and iterative prototyping. The starting point was doing customer insight work by spending a few hours with 20 people in their 20–40s that had recently been through cancer treatment. This was done in their home or with a researcher following them on their daily activities, so it was not just a normal interview, but an attempt to understand their lives in more detail than they could describe themselves in words. This gave great insight into what was important to these people and what their needs were after cancer. In analysing the vast amount of data, one finding was that they were struggling with their ‘new normal’, i.e. what a normal life feels like with the side effects of their disease or treatment. After a series of co-creational workshops to come up with ideas, people affected by cancer were also deeply involved throughout prototyping and testing of ‘pick me up’ offerings. In the early stages 20–30 people from the target audience were involved, but as the ideas evolved and the solution got more and more defined, 300 people took part in early testing of the service. It also meant continuous evaluation, i.e. was the solution having the impact it set out to have.

It is not only in the development of new services that Macmillan involve people affected by cancer, but across a spectrum of advisory boards, developing policy position, information resources and local services. It is in the knowledge of when and how to engage with our end customers that we can evolve the field of patient-centricity and people-driven solutions. From patients as experts to deep user insights, focus groups and early testing groups, a range of methods can help us and the people we serve.

There is no reason why pharma cannot do the same. Patients can be engaged in compliant and appropriate ways, and the benefits of listening to what they have to tell us are vast. This is how products and services will be created that better serve their needs. It is time for pharma to work with patients, and not just for them.

Marianne Guldbrandsen is Strategy Director at Cuttsy+Cuttsy, a healthcare strategy and comms agency, where people matter. Previously she spent five years building and heading up Macmillan Cancer Support’s Innovation & Strategic Partnership team. Coming from a design background, she set up a multidisciplinary team that has embedded design thinking across the organisation.

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Another year, another B!

Louise Jones, Cuttsy+Cuttsy's Sustainability Officer reflects on their latest year of carbon reporting through CDP and on achieving another B rating.

Jon Hume Joins Cuttsy+Cuttsy as New Commercial Director

Cuttsy+Cuttsy is excited to announce the appointment of Jon Hume as Commercial Director, effective 1st March 2024.

Clinical trial considerations: Why supporting HCPs matters...

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Clinical trial considerations: Why diversity matters...

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Clinical trial considerations: Why digital matters...

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.

Clinical trials explained: Why imagery matters...

Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...

Clinical trials explained: Why health literacy matters...

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...

Clinical trials explained: Why iconography matters...

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy+Cuttsy appoints Harriet Karia as Managing Director

Cuttsy+Cuttsy is pleased to announce the appointment of Harriet Karia as its first Managing Director.

Using generative AI in healthcare comms - our promise to our clients

It’s safe to say one of the hottest topics of 2023 has been ChatGPT and the launch of other Generative AI-driven applications. So, we’re sharing our promises, so that when...